Consistently, silencing FATP5 led to decreased AMPK activity and enhanced mTOR-S6K signaling in tumor samples, while stimulating the AMPK pathway by metformin treatment reversed these changes (Fig. 5H). The gene discussed is SLC27A5; the disease is neoplasm.